ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

9:00AM-10:30AM: Abstract Number: L04

Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: L06

Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: 1648

Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

9:00AM-10:30AM: Abstract Number: 1635

Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:00AM: Abstract Number: 1630

Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion

Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

9:00AM-10:30AM: Abstract Number: 1660

Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:30AM: Abstract Number: 1650

Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

9:00AM-10:30AM: Abstract Number: 1640

Tryptophan Metabolites Are Associated with Erosion and Symptoms in Hand Osteoarthritis: Results from the DIGICOD Cohort

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: 1643

Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: 1653

Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies

Abstracts: SLE – Treatment

10:30AM-11:30AM: Abstract Number: 1663

Age-Dependent Expansion and Activation of Disease-Associated Microglia in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models

10:30AM-11:30AM: Abstract Number: 1669

Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis

Abstracts: Immunological Complications of Medical Therapy

10:30AM-11:30AM: Abstract Number: 1671

Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients

Abstracts: Reproductive Issues in Rheumatic Disorders

10:30AM-11:30AM: Abstract Number: 1666

Differentiation of Injury-associated Macrophages in Lupus Kidneys Is Conserved in Humans and Lupus Mouse Models

Abstracts: SLE – Animal Models

10:30AM-11:30AM: Abstract Number: 1674

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth

Abstracts: Reproductive Issues in Rheumatic Disorders

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].